QC
ACRS icon

Quantessence Capital’s Aclaris Therapeutics ACRS Stock Holding History

Quantessence Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,664
Closed -$79K – 185
2025
Q1 		$79K Buy
+51,664
New +$110K 0.02% 315

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quantessence Capital's ACRS Position: Q2 2025 in Review

Quantessence Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 51,664 shares — an estimated $79K sold.

Quantessence Capital first reported a position in ACRS in Q1 2025 and held it in 1 quarter. The position peaked at $79K in Q1 2025. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Quantessence Capital reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 51,664 Aclaris Therapeutics shares in Q2 2025, an estimated $79K.
  • Quantessence Capital first reported a position in Aclaris Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Aclaris Therapeutics position peaked at $79K in Q1 2025.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.